Actionable news
All posts from Actionable news
Actionable news in GSK: GLAXOSMITHKLINE PLC,

GSK chases next biotech asthma drug with $230 million J&J deal

The GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013.

GlaxoSmithKline has bought global rights to an experimental drug from Johnson & Johnson for up to 175 million pounds ($230 million), raising its bet on a new generation of biotech medicines for severe asthma.

The British drugmaker recently launched Nucala, its first injectable biological asthma drug, and is looking for additional treatments to help more patients who are still struggling with breathing problems.

Up to 20 percent of asthma patients suffer from severe disease that is not well controlled with traditional inhalers. Nucala helps around a fifth of them, leaving considerable unmet need and a potentially large market, since severe asthma accounts for 70 to 80 percent of all asthma costs.

The new medicine, CNTO 7160, which is in Phase I...